⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Lanifibranor (Lanifibranor) | Accelerate Your Fibrosis Research

Home/Drugs/Lanifibranor

Lanifibranor

Lanifibranor

Phase 3

Sponsor: Inventiva

Indication: MASH

Mechanism of Action

Pan-PPAR Agonist

Target: PPAR-alphaTarget: PPAR-deltaTarget: PPAR-gamma

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT03459079

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Phase:PHASE2Org:University of Florida

RECRUITING

Relevant Publications (PubMed)

No recent publications found for Lanifibranor.

Validated Models

This drug has been validated in the following preclinical models:

NCT04849728

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Phase:PHASE3Org:Inventiva Pharma

COMPLETEDNCT03008070

Phase 2b Study in NASH to Assess IVA337

Phase:PHASE2Org:Inventiva Pharma

COMPLETEDNCT02503644

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Phase:PHASE2Org:Inventiva Pharma

COMPLETEDNCT03866369

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

Phase:PHASE1Org:Inventiva Pharma

View all trials on ClinicalTrials.gov